Skip to content
Nonprofiteer
← FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS

Form 990 for tax year 2023

Filed by FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS.

Totals

Total revenue
$6,525,815
Total expenses
$23,229,158
Contributions and grants received
$3,866,276
Grants paid
$18,691,164
Program service revenue
$0
Investment income
$2,734,710
Other revenue
-$75,171
Total assets, end of year
$58,430,242
Total liabilities, end of year
$18,609,384
Net assets or fund balances, end of year
$39,820,858
Program services expenses (Part IX)
$22,048,864
Management and general expenses
$973,515
Fundraising expenses
$206,779
Program service expenses (Part III)
$22,048,864

Program services were 94.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $768,600

  • 1f · All other contributions, gifts and grants

    $3,097,676

  • 3 · Investment income

    total $1,969,313 · excluded $1,969,313

  • 7a · Gross sales of assets other than inventory

    securities $6,421,099 · other assets $1,113,223

  • 7b · Less cost or other basis and sales expenses

    securities $6,768,925 · other assets $0

  • 7c · Gain or loss

    securities -$347,826 · other assets $1,113,223

  • 7d · Net gain or loss

    total $765,397 · excluded $765,397

  • 8a · Fundraising events: gross income

    $218,275

  • 8b · Fundraising events: direct expenses

    $309,678

  • 8c · Net income from fundraising events

    total -$91,403 · excluded -$91,403

  • 11a · Other revenue: MISCELLANEOUS

    total $16,232 · related or exempt $16,232

  • 11e · Other revenue, total

    $16,232

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $18,691,164 · program services $18,691,164

  • 5 · Compensation of officers, directors and key employees

    total $592,813 · program services $327,498 · management and general $214,673 · fundraising $50,642

  • 7 · Other salaries and wages

    total $781,826 · program services $572,378 · management and general $111,755 · fundraising $97,693

  • 11b · Fees: legal

    total $1,270,168 · program services $932,312 · management and general $337,856

  • 11f · Fees: investment management

    total $37,037 · management and general $37,037

  • 11g · Fees: other

    total $16,799 · program services $10,920 · management and general $4,100 · fundraising $1,779

  • 12 · Advertising and promotion

    total $19,730 · program services $19,730

  • 13 · Office expenses

    total $21,620 · management and general $21,620

  • 17 · Travel

    total $52,027 · program services $19,739 · management and general $32,288

  • 22 · Depreciation, depletion and amortization

    total $14,584 · program services $14,584

  • 23 · Insurance

    total $17,312 · management and general $17,312

  • 24a · Other expenses: COMMUNITY OUTREACH GALA

    total $619,355 · program services $619,355

  • 24b · Other expenses: EDUCATION AND AWARENESS

    total $428,418 · program services $428,418

  • 24c · Other expenses: EDUCATION AND AWARENESS

    total $309,678 · program services $309,678

  • 24d · Other expenses: COMPUTER AND SOFTWARE E

    total $140,829 · management and general $140,829

  • 24e · All other expenses

    total $215,798 · program services $103,088 · management and general $56,045 · fundraising $56,665

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $54,308,955 · end of year $701,529

  • 2 · Savings and temporary cash investments

    beginning of year $4,283,216 · end of year $47,521,755

  • 3 · Pledges and grants receivable

    beginning of year $2,316,785 · end of year $2,219,320

  • 4 · Accounts receivable

    beginning of year $237,629 · end of year $0

  • 10a · Land, buildings and equipment: cost or other basis

    $43,753

  • 10b · Land, buildings and equipment: accumulated depreciation

    $43,753

  • 10c · Land, buildings and equipment, net

    beginning of year $14,584 · end of year $0

  • 12 · Investments: other securities

    beginning of year $1,134,755 · end of year $7,919,012

  • 15 · Other assets

    beginning of year $779,430 · end of year $68,626

  • 17 · Accounts payable and accrued expenses

    beginning of year $226,506 · end of year $327,900

  • 18 · Grants payable

    beginning of year $7,033,207 · end of year $18,215,653

  • 25 · Other liabilities

    beginning of year $0 · end of year $65,831

  • 27 · Net assets without donor restrictions

    beginning of year $55,800,184 · end of year $39,805,401

  • 28 · Net assets with donor restrictions

    beginning of year $15,457 · end of year $15,457

Mission and programs · 2023

Mission

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Activities or mission (Part I)

THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) IS DEDICATED TO FINDING A CURE FOR ANGELMAN SYNDROME (AS) AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGGRESSIVE RESEARCH AGENDA, EDUCATION, AWARENESS, AND ADVOCACY.

  • FAST'S PRIMARY GOAL IS TO ADVANCE RESEARCH LEADING TO A CURE FOR AS IN THE FORM OF PROVIDING GRANTS TO UNIVERSITIES TO PERFORM RESEARCH AND TESTING.

    Expenses $18,691,164 · Grants $18,691,164

  • AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE DISORDER PRESENTS. IT IS ONE OF FAST'S OBJECTIVES TO EDUCATE, SUPPORT, AND STRENGTHEN THIS COMMUNITY.

    Expenses $3,357,700

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Ryan Jacob

    CHAIRPERSON

    Total calculated
    $0
    Hours/week
    18 + 4 related
  • Kelly David

    CO-VICE CHAIRPERSON

    Total calculated
    $0
    Hours/week
    20
  • Michael Hanrahan

    CO-VICE CHAIRPERSON AND TR

    Total calculated
    $0
    Hours/week
    10 + 2 related
  • Kristy Dixon

    TRESURER

    Total calculated
    $0
    Hours/week
    15 + 2 related
  • Amelia Beatty

    SECRETARY

    Total calculated
    $0
    Hours/week
    15 + 2 related
  • Roy Azout

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5
  • John Schlueter

    DIRECTOR

    Total calculated
    $0
    Hours/week
    30
  • Nora Xu

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5
  • Allyson Berent

    CHIEF SCIENCE OFFICER

    Total calculated
    $0
    Hours/week
    40 + 40 related
  • Lauren Hoffer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5
  • Megan Cross

    CHIEF INFORMATION OFFICER

    Total calculated
    $0
    Hours/week
    5
  • Ben O'Connor

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5 + 2 related
  • Kena Richert

    CHIEF FINANCIAL OFFICER

    Total calculated
    $191,948
    From this org
    $191,948
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $191,948
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $191,948
  • Alana Newhouse

    PRESIDENT/CEO

    Total calculated
    $177,800
    From this org
    $177,800
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $177,800
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $177,800
  • Ryan K Fischer

    CHIEF OPERATING OFICER

    Total calculated
    $198,051
    From this org
    $198,051
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $198,051
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $198,051
  • Maiddy Dunigan

    FORMER OFFICER AND COO

    Total calculated
    $36,755
    From this org
    $36,755
    From related orgs
    $0
    Other
    $0
    Hours/week
    0

    Schedule J breakdown matched by us

    Base
    $36,755
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $36,755

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Independent compensation consultant
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 3
THE BOARD OBTAINED A WRITTEN COMPENSATION ANALYSIS FROM WILLIS TOWERS WATSON, WHO SPECIALIZES IN EXECUTIVE COMPENSATION ASSESSMENTS. THE BOARD REVIEWED THIS COMPENSATION ANALYSIS, THE JOB DESCRIPTION, AND THE CURRENT NEEDS OF THE FOUNDATION TO SET THE COMPENSATION LEVELS FOR THE COO AND CFO POSITION.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

  • UPENN 2023: RESEARCH, COLLABORATION & LICENSE AGREEMENT

  • RUSH COE

  • FT2022-006: ABOM - NATURAL HISTORY STUDY

  • TEXAS A&M UNIVERSITY

    $267,142

    FT2019-008: TRANSLATIONAL RESEARCH IN PIG MODEL OF AS

  • FT2020-006: GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A

  • FT2022-002: TARGETING ANGELMAN SYNDROME THERAPEUTICS TO THE BRAIN UTILIZING NOVEL CELL PENETRATING PEPTIDES

  • FT2022-003: PEAK ALPHA FREQUENCY AS AN EEG BIOMARKER FOR ANGELMAN SYNDROME

  • FT2022-005: DEVELOPMENT OF BDNF POTENTIATING THERAPEUTICS FOR MOTOR AND COGNITIVE DYSFUNCTION IN AS

  • NORTH CAROLINA STATE UNIVERSITY

    $178,887

    FT2022-001: MICROPROBE-INTEGRATED HUMAN ORGANOID ARRAYS TO STUDY AS GENOTYPES AND THERAPEUTICS

  • NORTH CAROLINA STATE UNIVERSITY

    $161,647

    FT2021-002: ISOGENICALLY CONTROLLED HUMAN CELL LINES TARGETING ABERRANT IMPRINTING GENOTYPES AND A NEW REPORTER CELL LINE.

The 10 largest by cash amount. The API serves every itemized grant.

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Line Event 1 ANNUAL GALA Total
Gross receipts (line 1) $218,275 $218,275
Less contributions (line 2) — —
Gross income (line 3) $218,275 $218,275
Cash prizes (line 4) — —
Noncash prizes (line 5) — —
Rent and facility costs (line 6) — —
Food and beverages (line 7) — —
Entertainment (line 8) — —
Other direct expenses (line 9) $309,678 $309,678
Direct expenses (line 10)
$309,678
Net income (line 11)
-$91,403

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Related partnerships

Part III: related organizations taxable as a partnership, with the filer's share.

  • TRANFORMATX BIOTHERAPEUTICS LLC

    RELATED · MEDICAL RESEARCH · DE · 92.63% owned · share of income -$1,057,421 · share of assets $953,615 · general or managing partner

Provenance

Return type
form_990
Tax year
2023
Filed
15 November 2024
IRS schema version
2023v5.1
Source object
202423209349327812

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.